High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer-Reference-Cited by-同舟云学术

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer

Published:2018-03 Issue: Volume:117 Page:1-6
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ariyasu Ryo,Nishikawa Shingo,Uchibori Ken,Oh-hara Tomoko,Yoshizawa Takahiro,Dotsu Yosuke,Koyama Junji,Saiki Masafumi,Sonoda Tomoaki,Kitazono Satoru,Yanagitani Noriko,Horiike Atsushi,Inase Naohiko,Kasahara Kazuo,Nishio Makoto,Katayama Ryohei

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

3. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment;Lung Cancer;2024-04

2. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis;The Clinical Respiratory Journal;2024-04

3. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE;Nature Communications;2024-02-28

4. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib;Scientific Reports;2023-11-27

5. Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer;Drug Discovery Today;2023-09